LEI-101

• Description :

  LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC50 of 8 for hCB2, and a pKi of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors[1][2].

• UNSPSC :

  12352005

• Target :

  Cannabinoid Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/lei-101.html

• Concentration :

  10mM

• Purity :

  99.35

• Solubility :

  DMSO : 116.67 mg/mL (ultrasonic)

• Smiles :

  O=C1N(C2CC2)C(CN1CC3=CC=C(C4=NC(CN5CCS(CC5)(=O)=O)=C(F)C=C4)C=C3)=O.[H]Cl

• Molecular Formula :

  C23H26ClFN4O4S

• Molecular Weight :

  508.99

• References & Citations :

  [1]Mario van der Stelt, et al. Discovery and Optimization of 1- (4- (pyridin-2-yl) benzyl) imidazolidine-2,4-dione Derivatives as a Novel Class of Selective Cannabinoid CB2 Receptor Agonists. J Med Chem. 2011 Oct 27;54 (20) :7350-62.|[2]Partha Mukhopadhyay, et al. The Novel, Orally Available and Peripherally Restricted Selective Cannabinoid CB2 Receptor Agonist LEI-101 Prevents Cisplatin-Induced Nephrotoxicity. Br J Pharmacol. 2016 Feb;173 (3) :446-58.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2250025-91-1]